Trial design
toxicity, death
DRUG INTOLERANCE, DISEASE PROGRESSION, DISEASE, REMISSION
Our study was a prospective and randomized study. The ICd group was the experimental group, and the Id was the control group. Patients were randomly assigned to receive the ICd or Id regimen according to a random number table. Neither the investigator nor the patients could speculate on which group the next patients would be assigned to, and the person who determined the random number table would not participate in the inclusion of the patients. The grouping information was kept strictly.Patients who received at least two cycles were analyzed in this initial study. During the treatment, patients would withdraw from this study once there was poor response, progression of disease, death or drug intolerance. Patients who experienced progression would be assessed further, and subsequently be administered the appropriate regimens according to the possible mechanisms of resistance,Trial flow diagram. Id, ixazomib+dexamethasone; ICd, ixazomib+cyclophosphamide+dexamethasone. ORR, Partial remission or better. Withdrawal standard*, poor response, disease progression, death, and severe toxicity or requirement of patient. 